Infectious Diseases and Tropical Medicine Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Infectious Diseases and Tropical Medicine Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran; NRITLD, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Infect. 2014 Nov;69(5):424-9. doi: 10.1016/j.jinf.2014.06.010. Epub 2014 Jun 25.
Penetration and concentration of vancomycin is still an elusive and complex issue particularly in Cerebrospinal Fluid (CSF). The aim of this study was to clarify the penetration of this antimicrobial agent in CSF during meningeal inflammation.
In a prospective study, adult patients, with clinical and CSF analysis compatible with acute meningitis, who received vancomycin (15 mg/kg loading and 30 mg/kg daily maintenance dose) with ceftriaxone (4 gr/daily) were enrolled. CSF analysis including vancomycin trough levels before the fourth maintenance dose and during the 8-10th days of treatment, and simultaneous serum levels were performed by High-Pressure Liquid Chromatography (HPLC).
Twenty-seven patients (18 men, 9 women; mean age of 39.4 ± 14.7) were enrolled. The first serum trough level of vancomycin was 13.82 ± 1.28 mg/l. The mean of corresponding trough level in CSF was 11.2 ± 1.41 mg/l. The serum and CSF trough levels revealed positive linear correlation (r: 0.60) and was significant at the 0.01 level (P: 0.004). The penetration CSF/serum ratio was 0.811 ± 0.082 (coefficient of variation: 10.1%). The second trough levels of serum and CSF in (14 patients) vancomycin were 13.32 ± 1.02 and 10.64 ± 1.21, respectively. The serum and CSF trough levels revealed positive linear correlation (r: 0.71). The serum and CSF concentrations revealed no variation compared to the first trough levels.
Vancomycin has appropriate concentration in CSF during the treatment of meningitis and do not decrease along with the alleviation of meningeal inflammation in spite of concerns in this regard.
万古霉素的渗透和浓度仍然是一个难以捉摸且复杂的问题,尤其是在脑脊液(CSF)中。本研究旨在阐明该抗菌药物在脑膜炎症期间在 CSF 中的渗透情况。
在一项前瞻性研究中,纳入了临床和 CSF 分析符合急性脑膜炎的成年患者,他们接受万古霉素(负荷量 15mg/kg,维持量 30mg/kg 每日)和头孢曲松(4g/d)治疗。通过高效液相色谱法(HPLC)进行 CSF 分析,包括第四次维持剂量前和治疗第 8-10 天的万古霉素谷浓度,以及同时的血清水平。
共纳入 27 例患者(18 名男性,9 名女性;平均年龄 39.4±14.7 岁)。万古霉素的第一次血清谷浓度为 13.82±1.28mg/L。相应的 CSF 谷浓度平均值为 11.2±1.41mg/L。血清和 CSF 谷浓度呈正线性相关(r:0.60),在 0.01 水平上具有统计学意义(P:0.004)。CSF/血清渗透比值为 0.811±0.082(变异系数:10.1%)。第二次万古霉素的血清和 CSF 谷浓度分别为 13.32±1.02 和 10.64±1.21,共 14 例患者。血清和 CSF 谷浓度呈正线性相关(r:0.71)。与第一次谷浓度相比,血清和 CSF 浓度没有变化。
万古霉素在治疗脑膜炎期间 CSF 中的浓度合适,并且尽管存在这方面的担忧,但不会随着脑膜炎症的缓解而降低。